A Systematic Overview of Chemotherapy Effects in Colorectal Cancer

References

• Abdi EA, Hanson J, Harbora DE, et al. Adjuvant chemoimmuno- and immunotherapy in Dukes' stage B2 and C colorectal carcinoma: a 7-year follow-up analysis. J Surg Oncol 1989; 40: 205-13. (C1/253)
   Google Scholar
• Gastrointestinal Tumor Study Group. Adjuvant therapy of colon cancer-results of a prospectively randomized trial. New Engl J Med 1984; 310: 737-43. (C1/621)
   Google Scholar
• Hafstrom L, Domellof L, Rudenstam CM, et al. Adjuvant chemotherapy with 5-fluorouracil, vincristine and CCNU for patients with Dukes' C colorectal cancer. The Swedish Gastrointestinal Tumour Adjuvant Therapy Group. Br J Surg 1990; 77: 1345-8. (C2/345)
   Google Scholar
• Higgins GA, Donaldsson RC, Rogers LS, et al. Efficacy of MER immunotherapy when added to a regimen of 5-fluorouracil and methyl-CCNU following resection for car-cinoma of the large bowel. A Veterans Administration Surgical Oncology Group report. Cancer 1984; 54: 193-8. (C1/204)
   Google Scholar
• Panettiere FJ, Goodman PJ, Costanzi JJ, et al. Adjuvant therapy in large bowel adenocarcinoma: long-term results of a Southwest Oncology Group Study. J Clin Oncol 1988; 6: 947-54. (C1/626)
   Google Scholar
• Vernava AM. Adjuvant therapy for colorectal cancer. Cleveland Clin J Med 1992; 59: 603-7. (01)
   Google Scholar
• Wolmark N, Fisher B, Rockette H, et al. Postoperative adjuvant chemotherapy or BCG for colon cancer: results from NSABP protocol C-01. J Natl Cancer Inst 1988; 80: 30-6. (C1/1166)
   Google Scholar
• Boice JD, Greene MH, Killen JY, et al. Leukemia and preleukemia after adjuvant treatment of gastrointestinal cancer with semustine (methyl-CCNU). New Engl J Med 1983; 309: 1079-84. (L1)
   PubMed Web of Science ®Google Scholar
• Colorectal Cancer Chemotherapy Study Group of Japan. Five-year results of a randomized controlled trial of adju-vant chemotherapy for curatively resected colorectal car-cinoma. Jpn J Clin Oncol 1995; 25: 91-103. (C1/2001)
   Google Scholar
• Buyse M, Zeleniuch-Jacquofie A, Chalmers TC. Adjuvant therapy of colorectal cancer. Why we still don't know. JAMA 1988; 259: 3571-8. (M2/9853)
   Google Scholar
• Wolmark N, Rockette H, Fisher B, et al. The benefit of leucovorin-modulated fluorouracil as postoperative adju-vant therapy for primary colon cancer: results from Na-tional Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol 1993; 11: 1879-87. (C1/1081)
   Google Scholar
• Mamounas E, Wieand S, Wolmark N, et al. Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: Results from four Na-tional surgical adjuvant breast and bowel project adjuvant studies (C-01, C-02, C-03 and C-04). J Clin Oncol 1999; 17: 1349-55. (C1/1565)
   Google Scholar
• O'Connell MJ, Mailliard JA, Kahn MJ, et al. Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon can-cer. J Clin Oncol 1997; 15: 246-50. (C1/317)
   Google Scholar
• IMPACT. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 1995; 345: 939-44. (C1/1526)
   Google Scholar
• Scheithauer W, Komek G, Rosen H, et al. Combined in-traperitoneal plus intravenous chemotherapy after curative resection for colonic adenocarcinoma. Eur J Cancer 1995; 31A: 1981-6. (C2/121)
   Google Scholar
• Francini G, Petrioli R, Lorenzini L, et al. Folinic acid and 5-fluorouracil as adjuvant chemotherapy in colon cancer. Gastroenterol 1994; 106: 899-906. (C2/239)
   Google Scholar
• Windle R, Bell PR, Shaw D. Five year results of a ran-domized trial of adjuvant 5-fluorouracil and levamisole in colorectal cancer. Br J Surg 1987; 74: 569–72. (C3/141)
   Google Scholar
• Stevenson HC, Green I, Hamilton JM, et al. Levamisole: Known effects on the immune system, clinical results, and future applications to the treatment of cancer. J Clin Oncol 1991; 9: 2052-66. (01)
   PubMed Web of Science ®Google Scholar
• Arnaud JP, Buyse M, Nordlinger B, et al. Adjuvant ther-apy of poor prognosis colon cancer with levamisole: results of an EORTC double-blind randomized trial. Br J Surg 1989; 76: 284-9. (C1/297)
   Google Scholar
• Laurie JA, Moertel CG, Fleming TR, et al. Surgical adju-vant therapy of large-bowel carcinoma: An evaluation of levamisole and the combination of levamisole and fluorou-racil. J Clin Oncol 1989; 7: 1447-56. (C2/401)
   Google Scholar
• Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of re-sected colon carcinoma. N Engl J Med 1990; 322: 352-8. (C1/1296)
   Google Scholar
• Moertel CG, Fleming CG, MacDonald JS, et al. Fluorou-racil plus levamisole as effective adjuvant therapy after re-section of stage III colon cancer. A final report. Ann Intern Med 1995; 122: 321-6. (C1/971)
   Google Scholar
• Moertel CG, Fleming TR, MacDonald JS, et al. Inter-group study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer. J Clin Oncol 1995; 13: 2936-9. (C1/318)
   Google Scholar
• Zoetmulder F, Taal B, Tinteren HV. Adjuvant 5FU plus levamisole improves survival in stage II and III colonic cancer, but not in rectal cancer. Interim analysis of the Netherlands Adjuvant Colorectal Project (NACCP). Proc Am Soc Clin Oncol 1999; 18 Abstr 1021. (C3/1029)
   Google Scholar
• Gray R. Adjuvant therapy: how effective, and for which patients? A meta-analysis. Proc Eur Cancer Conf Org 9, 1997. Abstr 288. (M3/18000)
   Google Scholar
• Dube S, Heyen F, Jenicek M. Adjuvant chemotherapy in colorectal carcinoma. Dis Colon Rectum 1997; 40: 35-41. (M2/23011)
   Google Scholar
• Gastrointestinal Tumor Study Group. Prolongation of the disease-free interval in surgically treated rectal carcinoma. New Engl J Med 1985; 312: 1464-72. (C2/227)
   Google Scholar
• Fisher B, Wolmark N, Rockette H, et al. Postoperative adjuvant chemotherapy or radiation therapy for rectal can-cer: Results from NSABP Protocol R-01. J Natl Cancer Inst 1988; 80: 21-9. (C1/574)
   Google Scholar
• Krook JE, Moertel CG, Gunderson LL, et al. Effective surgical adjuvant therapy for high-risk rectal cancer. New Engl J Med 1991; 324: 709-15. (C1/204)
   Google Scholar
• Gastrointestinal Tumor Study Group. Radiation therapy and fluorouracil with or without semustine for the treat-ment of patients with surgical adjuvant adenocarcinoma of the rectum. J Clin Oncol 1992; 10: 5 49–57. (C1/210)
   Google Scholar
• Wolmark N, Rockette H, Mamounas EP, et al. The rela-tive efficacy fo 5FU and leucovorin, 5FU and levamisole in patients with Dukes B and C carcinoma of the colon: First report of NSABP C-04. Proc Am Soc Clin Oncol 1996; 15: Abstr 460. (C1/2151)
   Google Scholar
• Haller DG, Catalano PJ, Macdonald JS, et al. Fluorou-racil (FU), leucovorin (LV) and levamisole (LEV) adjuvant therapy for colon cancer: four-year results of INT-0089. Proc Am Soc Clin Oncol 1997; 16: Abstr 940. (C3/3759)
   Google Scholar
• O'Connell MJ, Laurie JA, Kahn M, et al. Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol 1998; 16: 295-300. (C1/915)
   Google Scholar
• Erlichman C, Marsoni S, Seitz JF, et al. Event free and overall survival by FUFA in resected B colon cancer: a pooled analysis of five randomized trials (ACTS). Proc Am Soc Clin Oncol 1997; 16: Abstr 991. (C3/998)
   Google Scholar
• IMPACT B2. Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. J Clin Oncol 1999; 17: 1356-63. (C1/1016)
   Google Scholar
• Norum J. Adjuvant chemotherapy in Dukes' B and C col-orectal cancer has only a minor influence on psychological distress. Supp Care Cancer 1997; 5: 318-21. (C2/95)
   Google Scholar
• Zaniboni A, Labianca R, Marsoni S, et al. GIVIO-SITAC 01: A randomized trial of adjuvant 5 fluorouracil and folinic acid administered to patients with colon carcinoma-long term results and evaluation of the indicators of health-related quality of life. Gruppo Interdisciplinare Va-lutazione Interventi in Oncologia. Studio Italiano Terapia Adiuvante Colon. Cancer 1998; 82: 2135-44. (C1/888)
   Google Scholar
• Taylor I, Machin D, Mullee M, et al. A randomized con-trolled trial of adjuvant portal vein cytotoxic perfusion in colorectal cancer. Br J Surg 1985; 72: 359-63. (C2/244)
   Google Scholar
• Wereldsma JC, Bruggink ED, Meijer WS, et al. Adjuvant portal liver infusion in colorectal cancer with 5-fluorou-racil/heparin versus urokinase versus control. Results of a prospective randomized clinical trial (colorectal adenocar-cinoma trial I). Cancer 1990; 65: 425-32. (C1/304)
   Google Scholar
• Wolmark N, Rockette H, Wickerham D, et al. Adjuvant therapy of Dukes' A, B and C adenocarcinoma of the colon with portal-vein fluorouracil hepatic infusion: prelim-inary results of National Surgical Adjuvant Breast and Bowel Project Protocol C-02. J Clin Oncol 1990; 8: 1466-75. (C1/1158)
   Google Scholar
• Wolmark N, Rockette H, Petrelli N, et al. Long-term re-sults of the efficacy of perioperative portal vein infusion of 5-FU for treatment of colon cancer: NSABP C-02. Proc Am Soc Clin Oncol 1994; 13: Abstr 561. (C3/1158)
   Google Scholar
• Beart RW Jr, Moertel CG, Wieand HS, et al. Adjuvant therapy for resectable colorectal carcinoma with fluorou-racil administered by portal vein infusion. A study of the Mayo Clinic and the North Central Cancer Treatment Group. Arch Surg 1990; 125: 897-901. (C1/224)
   Google Scholar
• Fielding LP, Hittinger R, Grace RH, et al. Randomised controlled trial of adjuvant chemotherapy by portal-vein perfusion after curative resection for colorectal adenocar-cinoma. Lancet 1992; 340: 502-6. (C1/398)
   Google Scholar
• Swiss Group for Clinical Cancer Research (SAKK). Long-term results of single course of adjuvant intraportal chemotherapy for colorectal cancer. Lancet 1995; 345: 349-53. (C1/533)
   Google Scholar
• Liver Infusion Meta-analysis Group. Portal vein chemotherapy for colorectal cancer: A Meta-analysis of 4000 patients in 10 studies. J Natl Cancer Inst 1997; 89: 497-505. (M1/3499)
   Google Scholar
• Rougier P, Sahmoud T, Nitti D. Adjuvant portal-vein in-fusion of fluorouracil and heparin in colorectal cancer: a randomised trial. Lancet 1998; 351: 1677-81. (L1)
   Google Scholar
• Gray R, James R, Mossman J, et al. AXIS-A suitable case for treatment. Br J Cancer 1991; 63: 841-5. (R2/13857)
   Google Scholar
• James RD. Intraportal 5FU (PVI) and pen-operative ra-diotherapy (RT) in the adjuvant treatment of colorectal cancer (CRCa)-3681 patients randomised in the UK Coor-dinating Committee on Cancer Research (UKCCCR) AXIS Trial. Proc Am Soc Clin Oncol 1999; 18: Abstr 1013. (C3/3861)
   Google Scholar
• Labianca R, Boffi L, Marsoni S, et al. A randomised trial of intraportal UP) versus systemic (SY) versus IP ± SY adjuvant chemotherapy in patients (pts) with resected Dukes B-C colon carcinoma (CC). Proc Am Soc Clin Oncol 1999; 18: Abstr 1014. (C3/1199)
   Google Scholar
• Riethmiiller G, Schnedier-Gädicke E, Schlimok G, et al. Randomised trial of monoclonal antibody for adjuvant therpay of resected Dukes' C colorectal carcinoma. Lancet 1994; 343: 1177-83. (C1/189)
   Google Scholar
• Riethmiiller G, Holz E, Schlimok G, et al. Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial. J Clin Oncol 1998; 16: 1788-94. (C1/189)
   Google Scholar
• Bleiberg H. Colorectal cancer-Is there an alternative to 5-FU? Eur J Cancer 1997; 33: 536-41. (L1)
   Google Scholar
• Kerr DJ. Clinical efficacy of `Tomudex' (raltitrexed) in ad-vanced colorectal cancer. Anticancer Drugs 1997; 8: 11-5. (L1/1361)
   Google Scholar
• Blackledge G. New developments in cancer treatment with the novel thymidylate synthas inhibitor raltitrexed (Tomudex). Br J Cancer 1998; 77 (Suppl. 2): 29–37. (L1)
   Google Scholar
• Moertel CG. Clinical management of advanced gastrointesti-nal cancer. Cancer 1975; 36: 675-82. (L2)
   Google Scholar
• Moertel CG. Chemotherapy for colorectal cancer. New Engl J Med 1994; 16: H36-42. (L2)
   Google Scholar
• Chisholm E, Malhotra A, Giles G. Quadraple chemotherapy for advanced colorectal cancer. Clinical Oncol 1983; 9: 185-6. (C3/24)
   Google Scholar
• Yorkshire Gastrointestinal Tumour Group. Chemotherapy after palliative resection of colorectal cancer. Br J Surg 1984; 71: 283-6. (C3/57)
   Google Scholar
• Scheithauer W, Rosen H, Komek GV, et al. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. Br Med J 1993; 306: 752-5. (C3/40)
   Google Scholar
• Nordic Gastrointestinal Tumor Adjuvant Therapy Group. Expectancy or primary chemotherapy in patients with ad-vanced asymptomatic colorectal cancer: A randomized trial. J Clin Oncol 1992; 10: 904-11. (C1/183)
   Google Scholar
• Glimelius B, Hoffman K, Graf W, et al. Cost-effectiveness of palliative chemotherapy in advanced gastrointestinal cancer. Ann Oncol 1995; 6: 267-74. (C3/21)
   Google Scholar
• Beretta G, Bollina R, Cozzi C, et al. Should we consider the weekly chemotherapy with fluorouracilracemic folic acida standard treatment for advanced/metastatic carcinoma of the digestive tract in elderly patients? Proc Am Soc Clin Oncol 1997; 16: Abstr 920. (C3/88)
   Google Scholar
• Allen-Mersh TG, Earlam S, Fordy, et al. Quality of life and survival with continuous hepatic-artery floxouridine infusion for colorectal liver metastases. Lancet 1994; 344: 1255-60. (C1/100)
   Google Scholar
• Hunt T, Flowerdew A, Birch S, et al. Prospective ran-domised controlled trial of hepatic arterial embolization or infusion chemotherapy with 5-Fluorouracil and degradable starch microspheres for colorectal liver metastases. Br J Surg 1990: 779–82. (C3/61)
   Google Scholar
• Rougier P, Laplanche A, Huguier M, et al. Hepatic arterial infusion of floxouridine in patients with liver metastases from colorectal carcinoma: Long-term results of a prospec-tive randomized trial. J Clin Oncol 1992; 10: 1112-8. (C1/ 166)
   Google Scholar
• Gerard A, Buyse M, Pector JC, et al. Hepatic artery ligation with and without portal infusion of 5-FU. A randomized study in patients with unresectable liver metastases from colorectal carcinoma. The EORTC Gastrointestinal Cancer Cooperative Group (GI Group). Eur J Surg Oncol 1991; 17: 289-94. (C3/74)
   Google Scholar
• Hafstrom L, Engaras B, Holmberg SB, et al. Treatment of liver metastases from colorectal cancer with hepatic artery occlusion, intraportal 5-fluorouracil infusion, and oral allop-urinol. Cancer 1994; 74: 2749-56. (C2/84)
   Google Scholar
• Cunningham D, Pyrhönen S, Cornelius R, et al. Ran-domised trial of irinotecan plus supportive care versus sup-portive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998; 352: 1413-8. (C1/ 189)
   Google Scholar
• Smyth J, Hardcastle J, Denton G, et al. Two phase III trials of tauromustine (TCNU) in advanced colorectal cancer. Ann Oncol 1995; 6: 948-9. (C3/190)
   Web of Science ®Google Scholar
• Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response. J Clin Oncol 1983; 1: 710-9. (L2)
   PubMed Web of Science ®Google Scholar
• Lavin P, Mittleman A, Douglass H, et al. Survival and response to chemotherapy for advanced colorectal adenocar-cioma. Cancer 1980; 46: 1536-43. (R1/1314)
   Google Scholar
• Graf W, Glimelius B, Palman L, et al. The relationship between an objective response to chemotherapy and survival in advanced colorectal cancer. Br J Cancer 1994; 70: 559-63. (R1/324)
   Google Scholar
• Buyse M, Piedbois P. On the relationship between response to treatment and survival time. Stat Med 1996; 15: 2797-812. (02)
   Google Scholar
• Fages B, Cote C, Gruia G, et al. Tumor response and stabilization rates are worthwhile surrogate efficacy end-points in metastatic colorectal cancer (CRC). Analysis of data in 455 5-FU resistant patients treated with CPT-11. Proc Am Soc Clin Oncol 1997; 16: Abstr 288. (R3/455)
   Google Scholar
• Glimelius B, Graf W, Hoffman K, et al. General condition of asymptomatic patients with advanced colorectal cancer receiving palliative chemotherapy: A longitudinal study. Acta Oncol 1992; 31: 645-51. (C2/36)
   Google Scholar
• Nordic Gastrointestinal Tumor Adjuvant Therapy Group. Sequential methotrexate/5-fluorouracffileucovorin (MFL) is superior to 5-fluorouracil alone in advanced symptomatic colorectal carcinoma. A randomized trial. J Clin Oncol 1989; 7: 1437-46. (C1/249)
   Google Scholar
• Glimelius B, Hoffman K, Olafsdottir M, et al. Quality of life during cytostatic therapy for advanced symptomatic col-orectal carcinoma. A randomized comparison of two regi-mens. Eur J Cancer Clin Oncol 1989; 25: 829-35. (C2/44)
   Google Scholar
• Nordic Gastrointestinal Tumor Adjuvant Therapy Group. Biochemical modulation of 5-fluorouracil: A randomized comparison of sequential methotrexate, 5-fluorouracil and leucovorin versus sequential 5-fluorouracil and leucovorin in patients with advanced symptomatic colorectal cancer. Ann Oncol 1993; 4: 235-41. (C1/202)
   Google Scholar
• Glimelius B, Hoffman K, Graf W, et al. Quality of life during chemotherapy in symptomatic patients with advanced colorectal cancer. Cancer 1994; 73: 556-62. (C2/70)
   Google Scholar
• Sullivan BA, McKinnis R, Laufman LR. Quality of life in patients with metastatic colorectal cancer receiving chemotherapy: a randomized, double-blind trial comparing 5-FU versus 5-FU with leucovorin. Pharmacotherapy 1995; 15: 600–7. (C1/210)
   Google Scholar
• Delfino C, Bosch B, Caccia G. Palliative results of chemotherapy in symptomatic patients with advanced col-orectal cancer. Proc Am Soc Clin Oncol 1997; 16: Abstr 1017. (P3/66)
   Google Scholar
• Borner MM, Castiglione M, Bacchi M, et al. The impact of adding low-dose leucovorin to monthly 5-fluorouracil in advanced colorectal carcinoma: results of a phase III trial. Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 1998; 9: 535-41. (C1/310)
   Google Scholar
• Cunningham D, Zalcberg JR, Rath U, et al. Tomudex' (ZD1694): results of a randomised trial in advanced col-orectal cancer demonstrate efficacy and reduced mucositis and leucopenia. The `Tomudex' Colorectal Cancer Study Group. Eur J Cancer 1995; 31A: 1945-54. (C1/439)
   Google Scholar
• Poon MA, O'Connell MJ, Moertel CG, et al. Biochemical modulation of fluorouracil: Evidence of significant improve-ment of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 1989; 7: 1407-18. (C2/ 429)
   Google Scholar
• Hill M, Norman A, Cunningham D, et al. Impact of pro-tracted venous infusion fluorouracil with or without inter-feron alfa-2b on tumor response, survival, and quality of life in advanced colorectal cancer. J Clin Oncol 1995; 13: 2317-23. (C1/160)
   Google Scholar
• Seymour MT, Slevin ML, Kerr DJ, et al. Randomized trial assessing the addition of interferon alpha-2a to fluorouracil and leucovorin in advanced colorectal cancer. Colorectal Cancer Working Party of the United Kingdom Medical Research Council. J Clin Oncol 1996; 14: 2280-8. (C1/260)
   Google Scholar
• Ross P, Norman A, Cunningham D, et al. A prospective randomised trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancer. Ann Oncol 1997; 8: 995-1001. (C1/200)
   Google Scholar
• Lokich J, Anderson N. Dose intensity for bolus versus infusion chemotherapy administration: Review of the litera-ture for 27 anti-neoplastic agents. Ann Oncol 1997; 8: 15-25. (L1)
   Google Scholar
• Diasio RB, Harris BE. Clinical pharmacology of 5-fluoro-uracil. Clin Pharmacokinet 1989; 16: 215-37. (01)
   Google Scholar
• Seifert P, Baker LH, Reed ML, et al. Comparison of contin-uously infused 5-fluorouracil with bolus injection in treat-ment of patients with colorectal adenocarcinoma. Cancer 1975; 36: 123-8. (C3/70)
   Google Scholar
• Lokich JJ, Ahlgren JD, Gullo JJ, et al. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study. J Clin On col 1989; 7: 425-32. (C1/179)
   Google Scholar
• Weinerman B, Shah A, Fields A, et al. Systemic infusion versus bolus chemotherapy with 5-fluorouracil in measurable metastatic colorectal cancer. Am J Clin Oncol 1992; 15: 518-23. (C1/184)
   Google Scholar
• Caudry M, Bonnel C, Floquet A, et al. A randomized study of bolus fluorouracil plus folinic acid versus 21-day fluorou-racil infusion alone or in association with cyclophosphamide and mitomycin C in advanced colorectal carcinoma. Am J Clin Oncol 1995; 18: 118-25. (C3/129)
   Google Scholar
• Hansen RM, Ryan L, Anderson T, et al. Phase III study of bolus versus infusion fluorouracil with or without cisplatin in advanced colorectal cancer. J Natl Cancer Inst 1996; 88: 668-74. (C1/497)
   Google Scholar
• Aranda E, Diaz-Rubio E, Cervantes A, et al. Randomized trial comparing monthly low-dose leucovorin and fluorou-racil bolus with weekly high-dose 48-hour continuous-infu-sion fluorouracil for advanced colorectal cancer: a Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD) study. Ann Oncol 1998; 9: 727-31. (C1/306)
   Google Scholar
• Weh H, Zschaber R, Braumann D, et al. A randomised phase III study comparing weekly folinic acid (FA) and high-dose 5-fluorouracil (5-FU) with monthly 5-FU/FA (days 1-5) in untreated patients with metastatic colorectal carcinoma. Onkologie 1998; 21: 403-7. (C1/149)
   Google Scholar
• Meta-analysis Group In Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998; 16: 301-8 (M1/1219)
   Google Scholar
• Larsson PA, Carlsson G, Gustavsson B, et al. Different intravenous administration techniques for 5-fluorouracil-pharmacokinetic and pharmacodynamic effects. Acta Oncol 1996; 35: 207-13. (R2/198)
   Google Scholar
• Glimelius B, Jacobsen A, Graf W, et al. Bolus injection (2-4 minutes) versus short-term (10-20 minutes) infusion of 5-fluorouracil in patients with advanced colorectal cancer: A prospective randomized trial. Eur J Cancer 1998; 34: 674-8. (C1/201)
   Google Scholar
• Moertel CG, Schutt AJ, Reimeier RJ, et al. A comparison of 5-Fluorouracil administered by slow infusion and rapid in-jection. Can Res 1972; 32: 2717-9. (C2/149)
   Google Scholar
• Hejna M, Kornek G, Raderer M, et al. 5-Methyltetrahydro-folate for biochemical modulation of fluorouracil (FU) in patients with advanced colorectal cancer: A randomised phase I-II study of two different FU administration sched-ules. Ann Oncol 1998; 9: 1309-14. (C3/79)
   Google Scholar
• Sobrero AF, Aschele C, Bertino JR. Fluorouracil in col-orectal cancer-A tale of two drugs: Implications for bio-chemical modulation. J Clin Oncol 1997; 15: 368-81. (L1)
   Google Scholar
• de Gramont A, Bosset JF, Milan C, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal can-cer: A French Intergroup Study. J Clin Oncol 1997; 15: 808-15. (C1/448)
   Google Scholar
• Loehrer JP, Turner S, Kubilis P, et al. A prospective ran-domized trial of fluorouracil versus fluorouracil plus cis-platin in the treatment of metastatic cancer: a Hoosier Oncology Group trial. J Clin Oncol 1988; 6: 642-8. (C2/141)
   Google Scholar
• Labianca R, Pancera G, Cesana B, et al. Cisplatin 5-fluorouracil versus 5-fluorouracil alone in advanced col-orectal cancer: a randomized study. Eur J Cancer Clin Oncol 1988; 24: 1579-81. (C3/60)
   Google Scholar
• Kemeny N, Israel K, Niedzwiecki D, et al. Randomized study of continuous infusion fluorouracil versus fluorouracil plus cisplatin in patients with metastatic cancer. J Clin Oncol 1990; 8: 313-8. (C1/122)
   Google Scholar
• Diaz-Rubio E, Jimeno J, Anton A, et al. A prospective randomized trial of continuous infusion 5-fluorouracil (5-FU) versus 5-FU plus cisplatin in patients with advanced colorectal cancer. A trial of the Spanish Cooperative Group for Digestive Tract Tumor Therapy (T.T.D.). Am J Clin Oncol 1992; 15: 56–60. (C1/160)
   Google Scholar
• Lokich J, Ahlgren J, Cantrell J, et al. A prospective random-ized comparison of protracted infusional 5-fluorouracil with or without weekly bolus cisplatin in metastatic colorectal carcinomas: a Mid-Atlantic Oncology Program study. Can-cer 1991; 7: 14-9. (C1/184)
   Google Scholar
• Petrelli N, Herrera L, Rustum Y, et al. A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J Clin Oncol 1987; 5: 1559-65. (C2/74)
   Google Scholar
• Valone FH, Friedman MA, Wittlinger PS, et al. Treatment of patients with advanced colorectal carcinoma with fluorou-racil alone, high-dose leucovorin plus fluorouracil, or se-quential methotrexate, fluorouracil, and leucovorin: a randomized trial of the Northern California Oncology Group. J Clin Oncol 1989; 7: 1427-36. (C1/265)
   Google Scholar
• Machiavelli M, Leone BA, Romero A, et al. Advanced colorectal carcinoma. A prospective randomized trial of sequential methotrexate, 5-fluorouracil, and leucovorin ver-sus 5-fluorouracil alone. Am J Clin Oncol 1991; 14: 211–7. (C2/125)
   Google Scholar
• Herrmann R, Knuth A, Kleeberg U, et al. Sequential methotrexate and 5-fluorouracil (FU) vs. FU alone in metastatic colorectal cancer. Results of a randomized multi-center trial. The Association of Medical Oncology (AIO) for the German Cancer Society. Ann Oncol 1992; 3: 539-43. (C1/172)
   Google Scholar
• Abad A, Garcia P, Gravalos C, et al. Sequential methotrex-ate, 5-fluorouracil (5-FU), and high dose leucovorin verus 5-FU and high dose leucovorin versus 5-FU alone for ad-vanced colorectal cancer. A multiinstitutional randomized trial. Cancer 1995; 75: 1238-44. (C2/178)
   Google Scholar
• Blijham G, Wagener T, Wils J, et al. Modulation of high-dose infusional fluorouracil by low-dose methotrexate in patients with advanced or metastatic colorectal cancer: final results of a randomized European Organization for Research and Treatment of Cancer Study. J Clin Oncol 1996; 14: 2266-73. (C1/310)
   Google Scholar
• Advanced Colorectal Cancer Meta-Analysis Project. Meta-analysis of randomized trials testing the biochemical modula-tion of fluorouracil by methotrexate in metastatic colorectal cancer. J Clin Oncol 1994; 12: 960-9. (M1/1178)
   Google Scholar
• Luporini G, Labianca R, Pancera G. Treatment of metastatic colorectal cancer: improvement of 5-fluorouracil activity with modulating agents. Forum 1991; 1: 246–56. (L2)
   Google Scholar
• Petrelli N, Douglass Jr HO, Herrera L, et al. The modulation of fluorouracil with leucovorin in metastatic colorectal car-cinoma: a prospective randomized phase III trial. Gas-trointestinal Tumor Study Group. published erratum appears in J Clin Oncol 1990 Jan; 8: 185. J Clin Oncol 1989; 7: 1419–26. (C1/343)
   Google Scholar
• Nobile MT, Rosso R, Sertoli MR. Randomised comparison of weekly bolus 5-fluorouracil with or without leucovorin in metastatic colorectal carcinoma. Eur J Cancer 1992; 28A: 1823–7. (C1/148)
   Google Scholar
• Labianca R, Pancera G, Aitini E, et al. Folinic acid ± 5-fluorouracil (5-FU) versus equidose 5-FU in advanced col-orectal cancer. Phase III study of `GISCAD' (Italian Group for the Study of Digestive Tract Cancer). Ann Oncol 1991; 2: 673-9. (C1/182)
   Google Scholar
• Doroshow JH, Multhauf P, Leong L, et al. Prospective randomized comparison of fluorouracil versus fluorouracil and high-dose continuous infusion leucovorin calcium for the treatment of advanced measurable colorectal cancer in pa-tients previously unexposed to chemotherapy. J Clin Oncol 1990; 8: 491-501. (C2/79)
   Google Scholar
• Erlichman C, Fine S, Wong A, et al. A randomized trial of fluorouracil and folinic acid in patients with metastatic col-orectal carcinoma. J Clin Oncol 1988; 6: 469-75. (C2/130)
   Google Scholar
• Martoni A, Cricca A, Guaraldi M, et al. Randomized clinical trial with a weekly regimen of 5-FU vs 5-FU ± intermediate-dose folinic acid in the treatment of advanced cob-rectal cancer: letter. Ann Oncol 1992; 3: 87-8. (02)
   PubMed Web of Science ®Google Scholar
• Connell MO. A phase III trial of 5-fluorouracil and leucov-orin in the treatment of advanced colorectal cancer. A Mayo Clinic/North Central Cancer Treatment Group study. Cancer 1989; 63 (Suppl. 6): 1026–30. (C1/208)
   Google Scholar
• Petrioli R, Lorenzi M, Aquino A, et al. Treatment of advanced colorectal cancer with high-dose intensity folinic acid and 5-fluorouracil plus supportive care. Eur J Cancer 1995; 31A: 2105-8. (C1/185)
   Google Scholar
• Di Costanzo F, Bartolucci R, Calabresi F, et al. Fluorouracil-alone versus high-dose folinic acid and fluorouracil in ad-vanced colorectal cancer. A randomized trial of the Italian Oncology Group for Clinical Research (GOIRC). Ann Oncol 1992; 3: 371-6. (C1/181)
   Google Scholar
• Laufman LR, Bukowski RM, Collier MA, et al. A random-ized, double-blind trial of fluorouracil plus placebo versus fluorouracil plus oral leucovorin in patients with metastatic colorectal cancer. J Clin Oncol 1993; 11: 1888-93. (C1/218)
   Google Scholar
• Leichman CG, Fleming TR, Muggia FM, et al. Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study. J Clin Oncol 1995; 13: 1303-11. (P1/620)
   Google Scholar
• Steinke B, Gunther E, Hirschmann WD, et al. Fluorouracil versus folinic acid/fluorouracil in advanced colorectal cancer-preliminary results of a randomized trial. Semin Oncol 1992; 19: 141-7. (C2/135)
   Google Scholar
• Advanced Colorectal Cancer Meta-Analysis Project. Modula-tion of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 1992; 10: 896-903. (M1/1382)
   Google Scholar
• Jager E, Heike M, Bernhard H, et al. Weekly high-dose leucovorin versus low-dose leucovorin combined with fluorouracil in advanced colorectal cancer: results of a ran-domized multicenter trial.Study Group for Palliative Treat-ment of Metastatic Colorectal Cancer Study Protocol 1. J Clin Oncol 1996; 14: 2274–9. (C1/291)
   Google Scholar
• Buroker TR, O'Connell MJ, Wieand HS, et al. Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer: see comments. J Clin Oncol 1994; 12: 14-20. (C1/372)
   Google Scholar
• Corfu-A Study Group. Phase III randomized study of two fluorouracil combinations with either interferon alpha-2a or leucovorin for advanced colorectal cancer. J Clin Oncol 1995; 13: 921-8. (C1/496)
   Google Scholar
• Valsecchi R, Labianca R, Cascinu S, et al. High dose (HD) versus low dose (LD) L-leucovorin (LLV) as a modulator of 5-day 5-fluorouracil (5FU) in advanced colorectal cancer (ACC): A GISCAD phase III study. Proc Am Soc Clin Oncol 1995; 14: Abstr 457. (C3/422)
   Google Scholar
• Goldberg R, Hatfield A, Kahn M, et al. Prospectively ran-domized North Central Cancer Treatment Group trial of intensive-course fluorouracil combined with the 1-isomer of intranenous leucovorin, oral leucovorin, or intravenous leu-covorin for the treatment of advanced colorectal cancer. J Clin Oncol 1997; 15: 3320-9. (C1/926)
   Google Scholar
• Scheithauer W, Kornek G, Maczell A, et al. Fluorouracil plus racemic leucovorin versus fluorouracil combined with the pure 1-isomer of leucovorin for the treatment of advanced colorectal cancer: A randomized phase III study. J Clin Oncol 1997; 15: 908-14. (C1/248)
   Google Scholar
• Kjaer M. Combining 5-fluorouracil with interferon-alpha in the treatment of advanced colorectal cancer: optimism fol-lowed by disappointment. Anticancer Drugs 1996; 7: 35-42. (L1/2275)
   Google Scholar
• York M, Greco FA, Figlin RA, et al. A randomized Phase III trial comparing 5-FU with or without interferon alpha 2a for advanced colorectal cancer. Proc Am Soc Clin Oncol 1993; 12: Abstr 590. (C3/245)
   Google Scholar
• Kohne CH, Wilke H, Hecker H, et al. Interferon-alpha does not improve the antineoplastic efficacy of high-dose infu-sional 5-fluorouracil plus folinic acid in advanced colorectal cancer. First results of a randomized multicenter study by the Association of Medical Oncology of the German Cancer Society (AI0). Ann Oncol 1995; 6: 461–6. (C2/149)
   Google Scholar
• Dufour P, Husseini F, Dreyfus B, et al. 5-Fluorouracil versus 5-fluorouracil plus alpha-interferon as treatment of metastatic colorectal carcinoma. A randomized study [see comments]. Ann Oncol 1996; 7: 575-9. (C2/105)
   Google Scholar
• Kreuser ED, Streit M, Kuchler T, et al. A multicenter randomized trial with the assessment of the quality of life in patients with metastatic colorectal carcinoma given either folinic acid or interferon a -2b as a modulator of 5-fluorou-racil. Proc Am Soc Clin Oncol 1995; 14: Abstr 485. (C3/142)
   Google Scholar
• Di Costanzo F, El-Taani H, Marzola M, et al. Hydroxyurea (HU), high dose folinic acid (1-FA) and 5FU vs HU, 5FU and interferon-alpha-2b (IFN) in advanced colorectal cancer (ACRC): a randomized trial of the Italian Oncology Group for Clinical Research (GOIRC). Proc Am Soc Clin Oncol 1995; 14: Abstr 508. (C3/232)
   Google Scholar
• Greco FA, Figlin R, York M, et al. Phase III randomized study to compare interferon alfa-2a in combination with fluourouracil versus fluorouracil alone in patients with ad-vanced colorectal cancer. J Clin Oncol 1996; 14: 2674-81. (C1/245)
   Google Scholar
• Kosmidis PA, Tsavarais N, Skarlos D, et al. Fluorouracil and leucovorin with or without interferon alpha-2b in ad-vanced colorectal cancer: analysis of a prospective random-ized phase III trial. Hellenic Cooperative Oncology Group. J Clin Oncol 1996; 14: 2682-7. (C1/106)
   Google Scholar
• Recchia F, Nuzzo A, Lalli A, et al. Randomized trial of 5-fluorouracil and high-dose folinic acid with or without alpha-2B interferon in advanced colorectal cancer. Am J Clin Oncol 1996; 19: 301-4. (C2/100)
   Google Scholar
• Hausmaninger H, Moser R, Samonigg H, et al. Biochemical modulation of 5-fluorouracil by leucovorin with or without interferon-alpha-2c in patients with advanced cancer: final results of a randomised phase III study. Eur J Cancer 1999; 35: 380-5. (C1/269)
   Google Scholar
• Kohne CH, Schoffski P, Wilke H, et al. Effective biomodu-lation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer. J Clin Oncol 1998; 16: 418-26. (C1/236)
   Google Scholar
• Valone FH, Kohler M, Fisher K, et al. A Northern Cali-forna Oncology Group randomized trial of leucovorin plus 5-fluorouracil versus sequential methotrexate, 5-fluorouracil, and leucovorin in patients with advanced colorectal cancer who failed with 5-fluorouracil or 5-fluorodeoxyuridine alone. NCI Monogr 1987; 5: 175-7. (C2/102)
   Google Scholar
• Budd GT, Fleming TR, Bukowski RM, et al. 5-fluorouracil and folinic acid in the treatment of metastatic colorectal cancer: a randomized comparison. A Southwest Oncology Group Study. J Clin Oncol 1987; 5: 272-7. (C2/128)
   Google Scholar
• Mustacchi G, Pavesi L, Milani S, et al. High-dose folinic acid (FA) and fluorouracil (FU) plus or minus thymostim-ulin (TS) for treatment of metastatic colorectal cancer: re-sults of a randomzed multicenter clinical trial. Anticancer Res 1994; 14: 617-9. (C1/211)
   Google Scholar
• Kohne CH, Hiddemann W, Schuller J, et al. Failure of orally administered dipyridamole to enhance the antineo-plastic activity of fluorouracil in combination with leucov-orin in patients with advanced colorectal cancer: a prospective randomized trial. J Clin Oncol 1995; 13: 1201-8. (C1/181)
   Google Scholar
• Heys SD, Eremin O, Ruggeri EM, et al. A phase III study of recombinant interleukin-2, 5-fluorouracil and leucovorin ver-sus 5-fluorouracil and leucovorin in patients with unre-sectable or metastatic colorectal carcinoma. Eur J Cancer 1995; 31A: 19-25. (C1/135)
   Google Scholar
• Colucci G, Maiello E, Leo S, et al. Biochemical modulation of fluorouracil with high dose methotrexate or folinic acid in advanced colorectal cancer patients. Gruppo Oncologico dell'Italia Meridionale (GOIM). Anticancer Res 1994; 14: 2157-62. (C2/104)
   Google Scholar
• Polyzos A, Tsavaris N, Giannopoulos A, et al. Biochemical modulation of fluorouracil: comparison of methotrexate, folinic acid, and fluorouracil versus folinic acid and fluorou-racil in advanced colorectal cancer: a randomized trial. Cancer Chemother Pharmacol 1996; 38: 292-7. (C2/83)
   Google Scholar
• Jones DV Jr, Winn RJ, Brown BW, et al. Randomized phase III study of 5-fluorouracil plus high dose folinic acid versus 5-fluorouracil plus folinic acid plus methyl-lomustine for patients with advanced colorectal cancer. Cancer 1995; 76: 1709-14. (C1/319)
   Google Scholar
• Levi FA, Zidani R, Vannetzel JM, et al. Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemother-apy with oxaliplatin, fluorouracil, and folinic acid (leucov-orin) in patients with colorectal cancer metastases: a randomized multi-institutional trial. J Natl Cancer Inst 1994; 86: 1608-17. (C2/92)
   Google Scholar
• Mackintosh J, Coates A, Swanson C, et al. Chemotherapy of advanced colorectal cancer. A randomized trial of sequential methotrexate and 5-fluorouracil. Am J Clin Oncol 1987; 10: 210–2. (C3/55)
   PubMed Web of Science ®Google Scholar
• Bedikian AY, Stroehlein JR, Karlin DA, et al. Chemother-apy for colorectal cancer with a combination of PALA and 5-FU. Cancer Treat Rep 1981; 65: 747-53. (C3/51)
   Google Scholar
• Engstrom PF, MacIntyre JM, Douglass HO Jr, et al. Com-bination chemotherapy containing semustine (MeCCNU) in patients with advanced colorectal cancer previoulsy treated with 5-fluorouracil (5-Fu). Am J Clin Oncol 1983; 6: 175-80. (C3/207)
   Google Scholar
• Brown TD, Fleming TR, Goodman PJ, et al. A randomized trial of two schedules of trimetrexate versus 5-fluorouracil in advanced colorectal cancer: a Southwest Oncology Group study. Anticancer Drugs 1995; 6: 219-23. (C2/310)
   Google Scholar
• Kemeny N, Yagoda A, Braun D Jr. Metastatic colorectal carcinoma. A prospective randomized trial of Methyl-CCNU, 5-Fluorouracil (5-FU) and vincristine (MOF) versus MOF plus streptozotocin (MOF-Strep). Cancer 1983; 51: 20–4. (C2/75)
   Google Scholar
• Presant CA, Denes AE, Liu C, et al. Prospective randomized reappraisal of 5-fluorouracil in metastatic colorectal car-cinoma. A comparative trial with 6-thioguanine. Cancer 1984; 53: 2610–4. (C2/176)
   Google Scholar
• Bedikian AY, Stroehlein J, Korinek J, et al. A comparative study of oral tegafur and intravenous 5-fluorouracil in pa-tients with metastatic colorectal cancer. Am J Clin Oncol 1983; 6: 181-6. (C2/82)
   Google Scholar
• Engstrom PF, MacIntyre JM, Mittelman A, et al. Chemotherapy of advanced colorectal carcinoma: fluorou-racil alone vs. two drug combinations using fluorouracil, hydroxyurea, semustine, dacarbazine, razoxane, and mito-mycin. A phase III trial by the Eastern Cooperative Oncol-ogy Group (EST:1278). Am J Clin Oncol 1984; 7: 313–8. (C2/232)
   Google Scholar
• Alberto P, Mermillod B, Germano G, et al. A randomized comparison of doxifluridine and fluorouracil in colorectal carcinoma. Eur J Cancer Clin Oncol 1988; 24: 559-63. (P2/52)
   Google Scholar
• Richards FD, Case LD, White DR, et al. Combination chemotherapy (5-fluorouracil, methyl-CCNU, mitomycin C) versus 5-fluorouracil alone for advanced previously un-treated colorectal carcinoma. A phase III study of the Pied-mont Oncology Association. J Clin Oncol 1986; 4: 565-70. (C1/130)
   Google Scholar
• Buroker TR, Moertel CG, Fleming TR, et al. A controlled evaluation of recent approaches to biochemical modulation or enhancement of 5-fluorouracil therapy in colorectal car-cinoma. J Clin Oncol 1985; 3: 1624-31. (C2/335)
   Google Scholar
• Andersen E, Pedersen H. Oral ftorafur versus intravenous 5-fluorouracil. A comparative study in patients with col-orectal cancer. Acta Oncol 1987; 26: 433-6. (C3/60)
   Google Scholar
• Kemeny N, Lokich JJ, Anderson N, et al. Recent advances in the treatment of advanced colorectal cancer. Cancer 1993; 71: 9-18. (L1/2932)
   Google Scholar
• Bajetta E, Colleoni M, Rosso R, et al. Prospective ran-domised trial comparing fluorouracil versus doxifluridine for the treatment of advanced colorectal cancer. Eur J Cancer 1993; 29A: 1658-63. (C1/222)
   Google Scholar
• Connell MO, Schutt AJ, Moertel CG, et al. A randomized clinical trial of combination chemotherapy in advanced col-orectal cancer. Am J Clin Oncol 1987; 10: 320-4. (C2/165)
   Web of Science ®Google Scholar
• Sugarbaker PH, Gianola FJ, Speyer JL, et al. Prospective randomized trial of intravenous v intraperitoneal 5-FU in patients with advanced primary colon or rectal cancer. Semin Oncol 1985; 12: 101-11. (C3/66)
   Google Scholar
• Ross PJ, Webb A, Cunningham D, et al. Infusional 5-fluorouracil in the treatment of gastrointestinal cancers: The Royal Marsden Hospital experience. Ann Oncol 1997; 8: 111-5. (01)
   Google Scholar
• Cunningham D, Zalcberg JR, Rath U, et al. Final results of a randomised trial comparing `Tomudex'® (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. Ann Oncol 1996; 7: 961-5. (C1/439)
   Google Scholar
• Harper P. Advanced colorectal cancen results from the latest raltitrexed (Tomudex®) comparative study. Proc Am Soc Clin Oncol 1997; 16: Abstr 802. (C3/495)
   Google Scholar
• Pazdur R, Vincent M. Raltitrexed (Tomudex®) versus 5-fluorouracil and leucovorin in patients with advanced col-orectal cancer: results of a randomized, multicenter, North American trial. Proc Am Soc Clin Oncol 1997; 16: Abstr 801. (C3/459)
   Google Scholar
• Ross PJ, Heron J, Cunningham D. Cost of treating ad-vanced colorectal cancer: a retrospective comparison of treatment regimens. Eur J Cancer 1996; 32A (Suppl. 5): 13–7. (R2/116)
   Google Scholar
• Maughan T, James R, Kerr D, et al. Preliminary results of a multicentre randomised trial comparing 3 chemotherapy reg-imens (de Gramont, Lokich and Raltitrexed) in metastatic colorectal cancer. Proc Am Soc Clin Oncol 1999; 18: Abstr 1007. (C3/905)
   Google Scholar
• de Gramont A, Figer A, Seymour M, et al. A randomised trial of leucovorin and 5-fluorouracil (5FU) with or without oxaliplatin in advanced colorectal cancer (CRC). Proc Am Soc Clin Oncol 1998; 17: Abstr 985. (C3/420)
   Google Scholar
• Levi F, Zidani R, Misset JL. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. International Organiza-tion for Cancer Chronotherapy. Lancet 1997; 350: 681-6. (C1/186)
   Google Scholar
• Giacchetti S, Perpoint B, Zidani R, et al. Phase III multicen-ter randomized trial of oxaliplatin added to chronomodu-lated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000; 18: 136-47. (C1/200)
   Google Scholar
• Rougier P, Van Cutsem E, Bajetta E, et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998; 352: 1407-12. (C1/267)
   Google Scholar
• Saltz L, Locker P, Pirotta N. Weekly irinotecan (CPT-11), leucovorin (LV), and fluorouracil (FU) is superior to daily x5 LV/FU in patients (PTS) with previously untreated metastatic colorectal cancer (CRC). Proc Am Soc Clin Oncol 1999; 18: Abstr 898. (C3/666)
   Google Scholar
• Douillard J, Cunningham D, Roth A, et al. A randomised phase III trial comparing irinotecan (IRI)5FU/folinicacid (FA) to the same schedule of 5FU/FA in patients (pts) with metastatic colorectal cancer (MCRC) as front line chemotherapy (CT). Proc Am Soc Clin Oncol 1999; 18: Abstr 899. (C3/387)
   Google Scholar
• Maiello E, Giuliani F, Gebbia V, et al. Bi-monthly folonic acid (FA) and 5-fluorouracil (FU) bolus and continuous infusion alone or irinotecan (CPT-11) for advanced col-orectal cancer (ACC): Preliminary results of a phase II randomised trial of the Southern Italy Oncology Group. Proc Am Soc Clin Oncol 1999; 18: Abstr 929. (C3/88)
   Google Scholar
• Douillard J, Cunningham D, Roth A, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355: 1041-7. (C1/387)
   Google Scholar
• Cutsem Ev, Pozzo C, Starkhammar H, et al. A phase II study of irinotecan alternated with five days bolus of 5-fluorouracil and leucovorin in first-line chemotherapy of metastatic colon cancer. Ann Oncol 1998; 9: 1199-204. (P1/ 31)
   Google Scholar
• Meropol NJ, Sonnichsen DS, Birkhofer MJ. Oral UFT plus leucovorin in patients with relapsed or refractory colorectal cancer. Oncology 1997; 11: 22-5. (P3/18)
   Google Scholar
• Meropol NJ, Rustum YM, Petrelli NJ, et al. A phase I and pharmacokinetic study of oral uracil, Ftorafur, and leucov-orin in patients with advanced cancer. Cancer Chemother Pharmacol 1996; 37: 581-6. (P3/26)
   Web of Science ®Google Scholar
• Pazdur R, Lassere Y, Rhodes V, et al. Phase II trial of uracil and tegafur plus oral leucovorin: An effective oral regimen in the treatment of metastatic colorectal carcinoma. J Clin Oncol 1994; 11: 2296-300. (P1/45)
   Google Scholar
• Pazdur R, Douillard J, Skillings J, et al. Multicenter phase III study of 5-fluorouracil (5-FU) or UFT in combination with leucovorin (LV) in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 1999; 18: Abstr 1009. (C3/816)
   Google Scholar
• Carmichel J, Popiela T, Radstone D, et al. Randomised comparative study of ORZEL (Oral Uracil/Tegafur) (UFT) plus leucovorin (LV) versus parenteral 5-fluorouracil (5-FU) plus LV in patient with metastatic colorectal cancer. Proc Am Soc Clin Oncol 1999; 18: Abstr 1015. (C3/380)
   Google Scholar
• Findlay M, Van Cutsem E, Kocha W, et al. A randomised phase 11 study of Xeloda (capecitabine) in patients with advanced colorectal cancer. Proc Am Soc Clin Oncol 1997; 16: Abstr 227. (P3/109)
   Google Scholar
• Twelves C, Harper P, Cutsem EV. A phase III trial (S014796) of Xeloda (Capecitabine) in previously untreated advanced/metatstatic colorectal cancer. Proc Am Soc Clin Oncol 1999; 18: Abstr 1010. (C3/602)
   Google Scholar
• Cox J, Pazdur P, Thibault A, et al. A phase III trial of XELODA (Capecitabine) in previosly untreated advanced/ metatstatic colorectal cancer. Proc Am Soc Clin Oncol 1999; 18: Abstr 1016. (C3/605)
   Google Scholar
• Kemeny N, Daly J, Reichman B, et al. Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. A randomized trial. Ann Intern Med 1987; 107: 459-65. (C2/163)
   Google Scholar
• Chang AE, Schneider PD, Sugarbaker PH, et al. A prospec-tive randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of col-orectal liver metastases. Ann Surg 1987; 206: 685-93. (C3/ 64)
   Google Scholar
• Hohn DC, Stagg RJ, Friedman MA, et al. A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: the Northern Californa Oncology Group trial. J Clin Oncol 1989; 7: 1646-54. (C2/142)
   Google Scholar
• Martin JJ, O'Connell MJ, Wieand HS, et al. Intra-arterial floxuridine vs systemic fluorouracil for hepatic metastases from colorectal cancer. A randomized trial. Arch Surg 1990; 125: 1022-7. (C3/74)
   Google Scholar
• Meta-Analysis Group in Cancer. Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. J Natl Cancer Inst 1996; 88: 252-8. (M1/654)
   Google Scholar
• Cohen AM, Kemeny NE, Kohne CH, et al. Is intra-arterial chemotherapy worthwhile in the treatment of patients with unresectable hepatic colorectal cancer metastases? Eur J Cancer 1996; 32A: 2195-205. (L2/611)
   Google Scholar
• Daly JM, Kemeny N, Sigurdson E, et al. Regional infusion for colorectal hepatic metastases. A randomized trial com-paring the hepatic artery with the portal vein. Arch Surg 1987; 122: 1273-7. (C3/25)
   Google Scholar
• Kemeny N, Seiter K, Niedzwiecki D, et al. A randomized trial of intrahepatic infusion of fluorodeoxyuridine with dex- amethasone verus fluorodeoxyuridine alone in the treatment of metastatic colorectal cancer. Cancer 1992; 69: 327-34. (C3/50)
   Google Scholar
• Lorenz M, Hottenrott C, Inglis R, et al. Prevention of extrahepatic disease during intraarterial floxuridine of col-orectal liver metastases by simultaneous systemic 5-fluorou-racil treatment? A prospective multicenter study. Gan To Kagaku Ryoho 1989; 16: 3662-71. (C3/46)
   Google Scholar
• Lorenz M, Hottenrott C, Maier P, et al. Continuous regional treatment with fluoropyrimidines for metastases from col-orectal carcinomas: influence of modulation with leucovorin. Semin Oncol 1992; 19: 163-70. (C3/221)
   Google Scholar
• Safi F, Bittner R, Roscher R, et al. Regional chemotherapy for hepatic metastases of colorectal carcinoma (continuous intraarterial versus continuous intraarterial/intravenous ther-apy). Results of a controlled clinical trial. Cancer 1989; 64: 379-87. (P2/64)
   Google Scholar
• Wagman LD, Kemeny MM, Leong L, et al. A prospective, randomized evaluation of the treatment of colorectal cancer metastatic to the liver. J Clin Oncol 1990; 8: 1885-93. (C2/91)
   Google Scholar
• Durand-Zaleski I, Roche B, Buyse M, et al. Economic implications of hepatic arterial infusion chemotherapy in treatment of nonresectable colorectal liver metastases. J Natl Cancer Inst 1997; 89: 790–5. (L2)
   Google Scholar
• Lorenz M, Mueller H. Randomized, multicenter trial of fluorouracil plus leucovorin administered either via hepatic arterial or intravenous infusion versus fluorodeoxyuridine administered via hepatic arterial infusion in patients with nonresectable liver metastases from colorectal cancer. J Clin Oncol 2000; 18: 243-54. (C2/168)
   Google Scholar